Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Hospital, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/1/2014 |
| Start Date: | June 2012 |
| Contact: | Ronald Dechert |
| Email: | rdechert@umich.edu |
| Phone: | 734-936-5237 |
A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
This is a null hypothesis study. The investigators hypothesize that there will be no
difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute
intervals after administration of either surfactant and there will be no differences in the
number of doses needed between the two surfactants in premature infants admitted to our
NICU.
difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute
intervals after administration of either surfactant and there will be no differences in the
number of doses needed between the two surfactants in premature infants admitted to our
NICU.
Premature newborn infants may have impaired lung function as a result of their prematurity.
When this occurs, the newborns show poor oxygen and carbon dioxide exchange and difficulty
in breathing. The reason for these symptoms is due in part to the lack of special chemicals
in the lungs, called phospholipids or surfactant. The lack of these special chemicals causes
the babies lung to be difficult to ventilate. Treatment of this condition can require
placing an artificial airway (endotracheal tube) into the babies windpipe (intubation) and
use of a breathing machine (ventilator). In addition, physicians frequently give these
special chemicals (phospholipid) through the childs airway. There are several different
types of phospholipids available for this treatment in newborns but very limited amount of
studies have been done to examine differences in the ability to ventilate between the
various types of surfactant. The investigators propose to examine immediate changes in
ability to ventilate (dynamic compliance) at specific time intervals after administration of
either type of surfactant; Curosurf or Survanta.
When this occurs, the newborns show poor oxygen and carbon dioxide exchange and difficulty
in breathing. The reason for these symptoms is due in part to the lack of special chemicals
in the lungs, called phospholipids or surfactant. The lack of these special chemicals causes
the babies lung to be difficult to ventilate. Treatment of this condition can require
placing an artificial airway (endotracheal tube) into the babies windpipe (intubation) and
use of a breathing machine (ventilator). In addition, physicians frequently give these
special chemicals (phospholipid) through the childs airway. There are several different
types of phospholipids available for this treatment in newborns but very limited amount of
studies have been done to examine differences in the ability to ventilate between the
various types of surfactant. The investigators propose to examine immediate changes in
ability to ventilate (dynamic compliance) at specific time intervals after administration of
either type of surfactant; Curosurf or Survanta.
Inclusion Criteria:
- Preterm infants between 28 and 31 6/7 weeks' gestational age
- Inborn to UM NICU
- < 12 hours of age
- Respiratory Distress Syndrome
- radiographic evidence
- need for endotracheal intubation
- Oxygen requirement > 30% FiO2
- Decision to give surfactant by the treatment team
Exclusion Criteria:
- Major congenital anomaly
- Sepsis syndrome in extremis
We found this trial at
1
site
Click here to add this to my saved trials
